. 2021 Feb 15;11(1):77–83.

Table 3.

Detailed analysis of the initial complete blood count ratios of patients

n (%)	All patients (n=285)	Patients with progressive disease (n=60)	P	Patients who needed anticytokine treatment (n=96)	P	Patients who needed intensive care (n=48)	P	Patients who needed intubation (n=41)	P	Patients who died (n=26)	P
Lymphocyte
<620/mcl	34 (11.9%)	12 (35.2%)	0.03	19 (55.9%)	0.004	14 (41.2%)	<0.001	11 (32.4%)	0.002	7 (20.6%)	0.013
≥620/mcl	251 (88.1%)	48 (19.1%)	0.03	77 (30.7%)	0.004	34 (13.5%)	<0.001	30 (11.9%)	0.002	19 (7.6%)	0.013
Neutrophil to lymphocyte ratio
>6	67 (23.5%)	23 (34.3%)	0.002	38 (56.7%)	<0.001	26 (38.8%)	<0.001	20 (29.9%)	<0.001	10 (14.9%)	0.059
≤6	218 (76.5%)	37 (16.9%)	0.002	58 (26.6%)	<0.001	22 (10%)	<0.001	21 (9.6%)	<0.001	16 (7.3%)	0.059
Platelet to lymphocyte ratio >350
>350	42 (14.7%)	14 (33.3%)	0.034	20 (47.6%)	0.042	16 (38%)	<0.001	12 (28.6%)	0.005	8 (19%)	0.016
≤350	243 (85.3%)	46 (18.9%)	0.034	76 (31.3%)	0.042	32 (13.2%)	<0.001	29 (11.9%)	0.005	18 (7.4%)	0.016
Complete Blood Count Score
0-1	247 (86.6%)	47 (19%)	0.033	76 (31%)	0.009	32 (13.2%)	<0.001	30 (12.2%)	0.006	19 (7.7%)	0.032
2-3	38 (13.4%)	13 (34.2%)	0.033	20 (52.6%)	0.009	16 (42.1%)	<0.001	11 (28.9%)	0.006	7 (18.4%)	0.032